These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 9885783

  • 1. Chronic dopamine D1, dopamine D2 and combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys: antiamphetamine effects and extrapyramidal side effects.
    Peacock L, Hansen L, Mørkeberg F, Gerlach J.
    Neuropsychopharmacology; 1999 Jan; 20(1):35-43. PubMed ID: 9885783
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Extrapyramidal side effects during chronic combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys.
    Peacock L, Jensen G, Nicholson K, Gerlach J.
    Eur Arch Psychiatry Clin Neurosci; 1999 Jan; 249(5):221-6. PubMed ID: 10591986
    [Abstract] [Full Text] [Related]

  • 4. Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.
    Lublin H, Gerlach J, Peacock L.
    Psychopharmacology (Berl); 1993 Jan; 112(2-3):389-97. PubMed ID: 7871047
    [Abstract] [Full Text] [Related]

  • 5. Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol.
    Peacock L, Gerlach J.
    Eur J Pharmacol; 1993 Jun 24; 237(2-3):329-40. PubMed ID: 8103465
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dopamine receptor agonist- and antagonist-induced behaviors in primates previously treated with dopamine receptor antagonists: the pathogenetic mechanisms of acute oral dyskinesia.
    Lublin H.
    Clin Neuropharmacol; 1995 Dec 24; 18(6):533-51. PubMed ID: 8681313
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. MK-801-induced dystonia in cebus monkeys.
    Madsen M, Lublin H.
    Clin Neuropharmacol; 1998 Dec 24; 21(6):333-8. PubMed ID: 9844788
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Roles of NMDA and dopamine D1 and D2 receptors in the acquisition and expression of flavor preferences conditioned by oral glucose in rats.
    Dela Cruz JA, Coke T, Icaza-Cukali D, Khalifa N, Bodnar RJ.
    Neurobiol Learn Mem; 2014 Oct 24; 114():223-30. PubMed ID: 25065714
    [Abstract] [Full Text] [Related]

  • 19. PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756.
    Abi-Dargham A, Simpson N, Kegeles L, Parsey R, Hwang DR, Anjilvel S, Zea-Ponce Y, Lombardo I, Van Heertum R, Mann JJ, Foged C, Halldin C, Laruelle M.
    Synapse; 1999 May 24; 32(2):93-109. PubMed ID: 10231129
    [Abstract] [Full Text] [Related]

  • 20. Attenuation of the locomotor-sensitizing effects of the D2 dopamine agonist bromocriptine by either the D1 antagonist SCH 23390 or the D2 antagonist raclopride.
    Wise RA, Carlezon WA.
    Synapse; 1994 Jul 24; 17(3):155-9. PubMed ID: 7974197
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.